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288Rationale and Design of the Genetic
Contribution to Drug Induced Renal
Injury (DIRECT) Study
Linda Awdishu1,2, Caroline M. Nievergelt3, Andrew Davenport4, Patrick T. Murray5,
Etienne Macedo6, Jorge Cerda7, Raj Chakaravarthi8, Satish P. Ramachandra Rao2,11,
Arthur Holden9, Stuart L. Goldstein10 and Ravindra L Mehta2
1Department of Clinical Pharmacy, University of California, La Jolla, California, USA; 2Department of Medicine, University of
California, La Jolla, California, USA; 3Department of Psychiatry, University of California, La Jolla, California, USA; 4UCL Centre
for Nephrology, Royal Free Hospital, UK; 5University College Dublin School of Medicine, Ireland; 6University of São Paolo, São
Paolo, Brazil; 7Albany Medical College, Albany, New York, USA; 8STAR Hospitals, India; 9International Serious Adverse Event
Consortium, USA; 10Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA;
and 11Sri Devaraj Urs Academy of Higher Education and Research, IndiaIntroduction: Nephrotoxicity from drugs accounts for 18% to 27% of cases of acute kidney injury. Deter-
mining agenetic predispositionmaypotentially be important inminimizing risk. The aimsof this study are as
follows: to determine whether a genetic predisposition exists for the development of drug-induced kidney
disease (DIKD), using genome-wide association and whole-genome sequencing studies; to describe the
frequency, course, risk factors, resolution and outcomesof DIKD cases; to investigate the role of ethnic/racial
variability in the genetics of DIKD; and to explore the use of different tools establishing causality of DIKD.
Methods: A total of 800 patients will be enrolled worldwide and blood samples for DNA collected. Data on the
patient risk factors, vital signs, laboratoryparameters, drugexposure, andDIKDcoursewill be recorded.Apanel
of nephrologistswill adjudicate all cases. Genome-wide association studieswill be conducted using population
controlsmatchedonbiogeographicancestry todeterminewhether there isageneticpredisposition toDIKD.The
primary endpoint is the identification of specific drug-related polymorphisms associatedwith DIKD. Secondary
endpoints include the following: frequency of DIKD by causal drug and drug combinations; DIKD genetic vari-
ability; exploration of causality assessment tools; risk factor identification; description of the course of DIKD,
including mortality and dialysis dependency at hospital discharge and 28 and 90 days post-event.
Results: Data are currently being analyzed. Results are pending.
Discussion: TheGeneticContribution toDrug InducedRenal Injury (DIRECT) studywill be thefirst observational
cohort study to investigate the genetic determinants of DIKD. If the trial is positive, its findings will potentially
translate into safer patient outcomes, by genotypic individualization of therapy and minimization of harm.
Kidney Int Rep (2016) 1, 288–298; http://dx.doi.org/10.1016/j.ekir.2016.08.010
KEYWORDS: AKI; antimicrobials; calcineurin inhibitors; nephrotoxicity; NSAIDs; pharmacogenomics
ª 2016 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).D rug-induced kidney disease (DIKD) is a commoncause of acute kidney injury (AKI) in ambulatory
and hospitalized patients. The phenotype of DIKD is
variable, as injury can occur in different structures of
the kidney including the vascular endothelium,
glomeruli, tubules, and interstitium. In addition, DIKD
can manifest as acute and/or chronic alteration of kid-
ney function with onset varying from hours to weeks.
It is often asymptomatic, and the diagnosis is based on
a biomarker change such as an increased serumspondence: Linda Awdishu, 9500 Gilman Drive, La Jolla,
rnia 92093, USA. E-mail: lawdishu@ucsd.edu
ved 1 July 2016; revised 10 August 2016; accepted 14 August
published online 23 August 2016creatinine (Scr) or urinary findings including protein-
uria and hematuria consistent with glomerular injury.
Common drug culprits include antimicrobials, calci-
neurin inhibitors and chemotherapeutic agents. Risk
factors for DIKD have been reported for individual
drugs; they can be patient-specific (e.g., age, chronic
kidney disease [CKD]), disease related (e.g., sepsis, vol-
ume depletion), and process of care related (e.g., drug
dose and duration). Most cases of DIKD resolve with
drug discontinuation or dose reduction. However, it
is recognized that recurrent or prolonged cases of
AKI may lead to the development or progression of
CKD. Effective strategies to predict DIKD may help to
reduce the risk of recurrent injuries.Kidney International Reports (2016) 1, 288–298
L Awdishu et al.: DIRECT Study Design and Rationale CLINICAL RESEARCHThe pharmacogenomics of DIKD remains to be
established. Similar to adverse drug reactions affecting
other organs, it is most likely that there will be inter-
play between a number of different genes and envi-
ronmental factors. The genes involved may affect
diverse cellular pathways, including drug metabolism
and transport, apoptosis, immune responses, and
cellular repair and regeneration. Several drugs interact
with organic anion transporters (OAT) and may cause
kidney injury due to intracellular accumulation caused
by alterations in OAT function.1 The genotype of 2
transporters, OCT2 and multi-drug and toxin extrusion
protein (MATE), contribute to the susceptibility of
cisplatin nephrotoxicity.2 Similar mechanisms could
operate for other drugs. The immune response in drug-
induced acute interstitial nephritis (AIN) has not
been well studied. Genetic polymorphisms in human
leukocyte antigens (HLAs) have been documented in
antibiotic-associated hepatotoxicity and may similarly
have a role in drug-induced AIN.3,4
Genomic approaches such as genome-wide associa-
tion studies (GWAS) and whole-genome sequencing
enable the detection of rare, serious adverse effects,
provided that a well-defined, reliable phenotype is
established. Given the recent success in identifying
genes associated with other adverse drug reactions,
including the liver,5 skin,6 and muscle injury,7 a similar
study to identify genetic factors relevant to the risk of
DIKD is timely. This would be helpful to personalize
drug treatment and to inform drug development pro-
cesseswhere nephrotoxicity limits the generation of new
drugs. The Genetic Contribution to Drug Induced Renal
Injury (DIRECT) study is an observational genomic
study of patients who have developed DIKD to deter-
mine the genetic predictors of DIKD occurring in adult
and pediatric patients from an international consortium
of investigators.
STUDY OBJECTIVES
The primary objective of the study is to identify
common polymorphisms in subjects with DIKD
compared to population-based controls using genome-
wide association analysis. Secondary objectives
include the following: to investigate the role of ethnic/
racial variability in the genetics of DIKD associated
with specific, high-volume drugs; to describe the
course, clinical risk factors, resolution, and outcomes of
DIKD; and to explore the utility of different causality
assessment tools when adjudicating cases of DIKD.
STUDY DESIGN
This study is an international, multi-center, observa-
tional cohort study of patients who have developedKidney International Reports (2016) 1, 288–298DIKD as defined by phenotype standardization.8 Drug-
induced kidney disease is a spectrum of injury that
often goes unrecognized. Phenotype standardization
allows for definition of the injury with the aim of
improving identification across a variety of clinical
settings.8 A panel of nephrologists, adult and pediatric,
and pharmacists convened to standardize the pheno-
type of DIKD for the purpose of inclusion into this
study; the phenotype is summarized in Table 1.8 The
DIRECT study will primarily focus on the AKI and
glomerular phenotypes, as it was believed that tubular
disorders and nephrolithiasis would be more difficult
to link to genetic polymorphisms. In addition, the
study will assess multi-drug injury, allowing up to 3
causal drugs, as the clinical spectrum of DIKD often
includes more than 1 causal agent.
For the primary endpoint, population-based controls
matched on ancestry will be used from the Population
Reference Sample (POPRES) database.9 Population-based
controls have been effectively used in previous genome-
wide association studies to examine the genetic basis of
serious, rare adverse events such as drug-induced liver
injury or skin hypersensitivity.5,6,10 Drug-exposed con-
trols allow greater account of possible covariates in the
development of the adverse reaction. However, it is often
impractical to perform prospective studies following up
drug-exposed patients for the development of nephro-
toxicity, given the low occurrence of this adverse event
and the resources required to study multiple drugs.
At inclusion into the study, subjects will have
already experienced kidney injury. Study time points
will be based on historical drug exposure and course of
injury, including baseline assessment, hospital admis-
sion (for inpatients), pre-drug exposure, start of drug
exposure, DIKD day, peak serum creatinine (Scr), drug
discontinuation or dosage adjustment, nadir Scr, hos-
pital discharge (for inpatients), 28 and 90 days post-
injury (Tables 2 and 3). These time points will enhance
causality assessment and inform on outcomes. Specif-
ically, the time points were chosen for the following
reasons: to establish temporal association between the
drug exposure and the injury; to determine the
maximal severity of injury; and to measure outcomes of
recovery including complete and partial resolution and
nonrecovery. Determination of AKI recovery has been
variably reported in the literature. For example, reso-
lution has been reported by the nadir Scr time point or
at hospital discharge as well as days 28 and 90. We will
use definitions proposed by the KDIGO guidelines,
determination of acute kidney disease at day 28 and
chronic kidney disease at day 90 postinjury. Studies
have demonstrated that nonrecovery from AKI is
associated with increased mortality.11,12289
Table 1. Primary and secondary criteria for individual phenotypes
Phenotype Acute kidney injury Glomerular disorder Nephrolithiasis Tubular dysfunction
Characteristics  ATNa
 AIN
 Osmotic nephrosis
 Hematuria,
 Proteinuria
 Crystalluria
 Nephrolithiasis
 Ultrasound findings of stone with
or without obstruction
 Renal tubular acidosis
 Fanconi syndrome
 SIADHb
 Diabetes insipidus
 Phosphate wasting
Primary criteria  Rise in Scr that presents as or pro-
gresses to stage 2 (KDIGO) 2
2.9  reference Scr or higher
 If child has baseline Scr <0.5 mg/dl,
must double Scr to get to 0.5 mg/dl
or above
 For the sub-acute phenotype, the rise
in Scr to stage 2 may occur over a
period of >7 days but <90 days
OR
 Decline by $50% from peak Scr
over 7 days in relation to change in
drug-dosing adjustment or
discontinuation within 2 wk
 For the sub-acute phenotype, the
decline in Scr may occur between 7
and 90 days of drug discontinuation
or dose adjustment
 Biopsy-proven drug-induced glomerular
disease (within 4 wk of stopping drug)
AND
Proteinuria as defined by:
 24-h collection >1 g protein
 UPC or UACR > 0.8
 Urinalysis 2þ protein 100300 mg/dl
albumin
 Children: 100 mg/m2/d or 4 mg/m2/h
Hematuria
 >50 RBC/HPF
 Must be new onset following
drug exposure with no prior
history of nephrolithiasis
 No evidence of congenital etiol-
ogy for nephrolithiasis
 If obstructive, rise in Scr that
presents as or progresses to
stage 2 (KDIGO) or higher
 If non-obstructive, then:
 Urinalysis with crystals
 Ultrasound with stone
Tubular:
Hypo-phosphatemia
OR
Glycosuria
 Urinalysis with 3þ glucose without
diabetes
OR
Hyperchloremic metabolic
acidosis
AND
Hypokalemia or hyperkalemia
Diabetes insipidus:
 Hypernatremia > 155 mEq/l on
multiple occasions
 Polyuria > 3 L/d
Secondary criteria  Oliguric <500 ml/d or <0.5 ml/kg/h
for 12 h (KDIGO Stage 2)
 Non-oliguric >500 ml/day, >1 ml/
kg/h for 24 h (pediatrics)
 Urinalysis findings: granular and
muddy casts consistent with ATN,
urinary eosinophils, proteinuria
 FeNa > 1%
 Negative ultrasound findings
 Positive gallium scan for AIN
 Clinical symptoms for AIN: fever,
rash, joint pains
 Culture-negative leukocyturia
 >50 WBC/HPF
 Casts
 RBC; granular
 Absence of secondary disorder that can
cause GN: DM, lupus, post-infection,
hepatitis, and others
 Micro-angiopathic changes in blood
 Smear, LDH; haptoglobin
 Nephritic, nephrotic, mixed
 Urine electrolytes
 Stone workup
Phosphaturia
 FePO4 > 5%
 Urinary PO4 excretion > 100 mg/d
Hypomagnesemia
 Serum magnesium < 1.2 mg/dl
Hypouricemia
 Serum uric acid < 2 mg/dl
Tubular proteinuria
 24-h collection < 1 g protein
 UPC < 0.8
 Urinalysis < 2þ protein
Diabetes insipidus
 Serum osmolality > 300 mosm/kg
 Urine osmolality < 100 mOsm/kg
 Urine sodium < 10 mEq/l
AIN, acute interstitial nephritis; ATN, acute tubular necrosis; DM, diabetes mellitus; FeNa, fractional excretion of sodium; FePO4, fractional excretion of phosphorus; GN, glomerulo-
nephritis; HPF, high-powered field; LDH, lactate dehydrogenase; RBC, red blood cell; SIADH, syndrome of inappropriate antidiuretic hormone; UACR, urine albumin to creatinine ratio;
UPC, urine protein to creatinine ratio; WBC, white blood cell.8
aHemodynamic changes may contribute to ATN, however, in the absence of any specific features are not considered individual criteria for the AKI phenotype.
bSIADH does not reflect direct tubular damage but rather the impact of a drug on ADH secretion and subsequent impaired water handling.
CLINICAL RESEARCH L Awdishu et al.: DIRECT Study Design and RationaleThe following medications or medication clas-
ses will be included in the study: antivirals;
anti-retrovirals; aminoglycosides; amphotericin;
cephalosporins; chemotherapeutic agents; colistin;
calcineurin inhibitors; hydralazine; nonsteroidal anti-
inflammatory drugs; pamidronate; penicillins; pro-
pylthiouracil; proton pump inhibitors; quinolones;
rifampin; sulfamethoxazole/trimethoprim; vancomy-
cin; and additional medications to be added as
identified.
Study Population
Previously identified or new cases of DIKD will be
recruited, as conducting prospective studies on drug-
exposed patients to follow them up for the develop-
ment of nephrotoxicity would be impractical given the
low incidence of reactions reported for some drugs.
This current approach allows enrollment of a greater290number of case patients who have experienced toxicity
from a spectrum of drugs.
Subjects who have developed DIKD will be identified
by investigators and recruited from hospitals or ambu-
latory care clinics through 2 main approaches (Figure 1):
1. Recall and review of medical records of discharged
patients who had DIKD: Patients who developed
DIKD previously will be identified through recall, a
review of kidney biopsy logs, or previous nephrology
consults. Theywill be contacted for participation, and
informed consent will be obtained.2. Concurrent identification of patients under active
treatment: Patients in the hospital or in ambulatory
care clinics, who developed DIKD as defined by the
primary and secondary criteria in Table 2, will be
recruited for the study. They will be identified
through screening electronic medical records (EMR)Kidney International Reports (2016) 1, 288–298
Table 2. Schedule of assessments: Hospitalized subjects
Variable
Hospital
day 1
PreLdrug
exposure
Day of drug
exposure
Day of
DIKI
Peak Scr or peak severity
of injury
Drug DC or dosage
adjustment
Nadir Scr or resolution
of eventa
Hospital
DC
Status at days 28
and 90
Demographics X
Primary criterionb X X X X X X X
Etiology of DIKI X X
Duration of DIKI X X
Risk factors for DIKI X X X X X X X X
Drug dosing and
concentrations
X X X X X X
Concomitant drugs X X X X X X X X
History and physical
examination
X X X X X X X X
Hemodynamics and
fluid balance
X X X X X X X X
Other organ involvement X X X X X X X X
SOFA scorec X X X X X X X X
Sepsis scorec X X X X X X X
Laboratory and imaging
data
X X X X X X X X
Assessment of renal
function
X X X X X X X X X
Blood for DNA and
biomarkersd
X
Urine for biomarkersd X
Kidney biopsy if done X
Dialysis requirements X X X X X X
Hospital LOS X
Survival status X X
DC, discontinuation; DIKD, drug-induced kidney injury; LOS, length of stay; Scr, serum creatinine; SOFA, sequential organ failure assessment.
aIf no resolution, data at day 14.
bCapture reference and other elements.
cComputed.
dIf feasible; otherwise can be at any time point when consent is obtained.
L Awdishu et al.: DIRECT Study Design and Rationale CLINICAL RESEARCHwhen available. In the absence of an EMR, ne-
phrologists will identify potential subjects from
their consult service or from referral from a
colleague. If deemed appropriate by their primary
physicians, identified case patients will be
approached for participation and consent.
Inclusion criteria include all patients aged $2 years
who are exposed to a candidate drug for at least 24 hoursTable 3. Schedule of assessments: Ambulatory subjects
Variable Pre-drug Exposure Drug exposure Da
Demographics X
Primary criteriona X
Etiology of DIKI
Duration of DIKI
Drug dosing history and concentrations X
History and physical examination X
Laboratory and imaging assessment X X
Assessment of renal function X X
Concomitant drugs X X
Blood for DNAb
Dialysis requirements
Survival status
DC, discontinuation; DIKD, drug-induced kidney injury; Scr, serum creatinine.
aCapture reference and other elements.
bIf feasible, otherwise can be at any time point when consent is obtained.
Kidney International Reports (2016) 1, 288–298and develop the AKI or glomerular injury as defined by
the primary criteria for these phenotypes (Table 2).8
Exclusion criteria are as follows: history of or cur-
rent kidney transplant recipient; history of or current
stem cell transplant recipient; CKD stage 5; patient
receiving more than 3 causal drugs as determined by
the investigators; and incomplete patient information
on the time course of drug exposure.y of DIKI
Peak Scr or Peak
severity of injury
Drug DC or
dosage adjustment
Nadir Scr or
Resolution of event
X X X X
X X
X
X X X X
X X X X
X X X X
X X X X
X X X X
X
X X X X
X
291
Figure 1. Screening approach for the Genetic Contribution to Drug Induced Renal Injury (DIRECT) study. This figure demonstrates the 2 main
approaches to screening subjects who have developed drug-induced kidney injury. The first approach is direct recall of cases in which the
investigators have consulted or provided clinical care. The second approach uses electronic surveillance of case patients who have recently
developed drug-induced injury and are currently being hospitalized or receiving care at an outpatient clinic.
CLINICAL RESEARCH L Awdishu et al.: DIRECT Study Design and RationalePatients will be screened electronically for inclu-
sion into the study using electronic screening in a
Web-based database, www.obriendata.org/direct (last
accessed June 2016). Electronic screening will ensure
that phenotype criteria from Table 2 are met in relation
to the time frame for drug exposure (Supplementary
Appendix S1). Reasons for screen and consent failure
are recorded. Electronic screening allows for tracking
the screened population and most common reasons for
screen failure. In addition, this strategy allows for
determination of consenting rates.
This study protocol was approved by the UC San
Diego Human Research Protection Program (reference
#121651). Participating centers will obtain ethics
approval through their local ethics committees. All
patients will be asked to give their written informed
consent to participate in the study. Surrogate consent
will be requested if a subject lacks the capacity to
provide consent. Participating centers will follow their
local ethics committee regulations for consenting pro-
cedures. This study was registered as clinical trial
number NCT02159209 at www.ClinicalTrials.gov (last
accessed June 2016).
DATA COLLECTION
Data will be entered into a Web-based database, www.
obriendata.org/direct (last accessed June 2016). Data
validity and integrity is ensured by electronic rules
such as maximum/minimum value checking. Alerts are
issued on data in question, and users are required to
verify accuracy of data. At baseline, demographics
including age, sex, height, weight, self-reported
race/ethnicity, and medical history will be obtained
from the medical record, including co-morbidities,
reason for hospital admission or clinic appointment,292nephrology consultation notes, renal biopsy findings
and previous surgeries or procedures. The following
data will be collected at all time points (Supplementary
Appendix S1):
1. Physical examination: The presence of heart abnor-
malities, peripheral or pulmonary edema, ascites,
jaundice, indwelling bladder catheter, as well as any
active infections will be recorded.2. AKI risk factors: Risk factors for AKIwill be recorded,
including the following: exposure to contrast agents,
surgical procedures, need for blood transfusion,
nephrotoxic exposures, hypotension (systolic blood
pressure < 90 mm Hg or mean arterial pressure < 65
mm Hg), hyperglycemia (blood sugar > 110 mg/dl),
intravascular fluid losses (burns, hypovolemia, hem-
orrhage, paracentesis, or diuresis), sepsis, cardiac
failure, and liver disease.3. Vital signs: Height, weight, blood pressure, tem-
perature, respiratory rate, fluid balance, and intake/
output will be recorded. If the patient is in the
intensive care unit, we will record the following (if
available): central venous pressure, cardiac output,
fraction of inspired oxygen, arterial blood gases, and
Glasgow Coma Scale score.4. Laboratory tests: Standard-of-care comprehensive
metabolic panel, complete blood counts, and coag-
ulation study results will be recorded. Each
participating site will process its own standard-of-
care laboratory tests. Interventions will be deter-
mined by the attending physicians and not
influenced by the study personnel.5. Urinary studies: Standard-of-care urinalysis, urine
microscopy, cytology, and urine chemistry study
results will be recorded.Kidney International Reports (2016) 1, 288–298
L Awdishu et al.: DIRECT Study Design and Rationale CLINICAL RESEARCHAfter the development of AKI, the following infor-
mation will be collected:
1. Renal replacement therapies: The reason for initi-
ating dialysis, type of dialysis, start and stop dates of
dialysis, and dialysis discontinuation will be
recorded.2. Survival status: The subject’s survival status will be
established by review of the EMR and telephone
contact with patient at hospital discharge and days
28 and 90.3. Serum creatinine: Standard-of-care laboratory assess-
ment of Scr will be recorded from the EMR at hospital
discharge and days 28 and 90.
ADJUDICATION
Cases must pass adjudication by a panel of adult and
pediatric nephrologists to be included the final anal-
ysis. Kidney injury is often multifactorial, and adju-
dication is required to determine the underlying
causes.13 An adjudication process for evaluating DIKD
has not been previously developed. Prior published
processes for adjudication of drug-induced liver injury
and skin hypersensitivity were used as a framework for
designing adjudication of DIKD.14,15 Two independent
nephrologists will review each blinded case, presented
as a summary of completed data (Supplementary
Figure S1), to ascertain causality for DIKD and to
assess the contribution of risk factors for the develop-
ment of kidney injury. Specifically, the adjudicator
will make a determination of DIKD, and will evaluate
the relative contribution of each causal drug and the
relative contribution of recorded AKI risk factors
(Supplementary Appendix S1). Considering that adju-
dication processes for DIKD have not been previously
published, this study will investigate the reliability
and validity of this adjudication tool.
BIOLOGICAL SAMPLES
Each subject will provide 15 to 50 ml of urine
for biomarkers and 15 ml of blood for DNA and bio-
markers. DNA will be isolated from a whole-blood
sample and stored at the UCSD O’Brien Core Labora-
tory for genetic analysis. Centers will retain a 5-ml blood
sample for DNA at their site for back-up if the original
sample sent to the O’Brien Center was lost or destroyed.
DNA Preparation and Genotyping
Genomic DNA will be prepared from blood leukocytes
at UCSD’s Institute for Genomic Medicine facility, and
samples will be genotyped at the Broad Institute, using
the Illumina Human Core plus Exome (or similar
GWAS) array.Kidney International Reports (2016) 1, 288–298PROTOCOL DEFINITIONS
Because DIKD includes different mechanisms and sites of
injury, the clinical presentation can be categorized into 4
major phenotypes, including AKI, tubular dysfunction,
glomerular disorders, and nephrolithiasis (Table 2).
AKI
A process that causes an abrupt reduction in kidney
function and is defined by meeting any of the
following criteria16:
(i) An absolute increase in Scr ($0.3 mg/dl or $26.4
mmol/l) (within 48-hour time window) from the
reference Scr value.(ii) A percentage increase in Scr of $50% (1.5-fold
from reference) within 7 days.(iii) A reduction in urine output (documented oliguria
of <0.5 ml/kg/h for >6 hours) despite adequate
fluid resuscitation when applicable.(iv) An absolute decrease in Scr of$0.3 mg/dl or$26.4
mmol/l (within 48-hour time window) from the
reference Scr.(v) A relative decrease in Scr of $50% (1.5-fold from
reference) within 7 days.
Subacute DIKD
A process that causes a slower reduction in kidney
function and is defined by meeting any of the
following criteria:
(i) A percentage increase in Scr of $50% (1.5-fold from
reference) occurring between 7 and 90 days after the
initiation of the drug or within 2 weeks of drug
discontinuation.(ii) A relative decrease in Scr of $50% (1.5-fold from
reference) within 90 days of a change in drug
dosing or discontinuation.
CKD
Prior evidence of markers of kidney damage for
$3 months (microalbuminuria or proteinuria or
abnormalities in imaging tests) or the presence of
glomerular filtration rate (GFR) < 60 ml/min/1.73 m2
for $3 months calculated with the Modification of Diet
in Renal Disease (MDRD) equation.17,18 Chronic kidney
disease will be staged from stage 1 to 5 based on the
calculated CKD-EPI or Ckid (pediatrics) GFR.19,20
Reference Scr to Determine Timing of AKI
The following criteria will be used in order of prefer-
ence, depending on available values:
a) Lowest Scr immediately prior to index event. Must
meet the following criteria:293
CLINICAL RESEARCH L Awdishu et al.: DIRECT Study Design and Rationale
294a. Precedes drug exposure
b. Within 90 days of index event
c. Closest value to index event
d. Lowest value prior to drug exposure
e. If no Scr within 90 days of index event, will use
the hospital admission creatinine value
b) For declining Scr criteria with no prior reference
level, will use the lowest value post drug reduction
or stoppage as referencec) For AKI phenotype, will have 2 reference Scr values:
a. Reference 1:i. Lowest value within 90 days of initiation of
primary drugb. Reference 2:
i. Lowest value closest to initiation of drugBaseline Scr to Determine CKD Status
Creatinine values >90 days from index event
(i) Lowest values within 90 days to 12 months to estab-
lish eGFR stage based on CKD-EPI or Ckid (pediatrics)
(ii) Historical evidence of CKD based on standard
criteria: proteinuria, biopsy, ultrasound findings
(iii) Imaging studies consistent with CKD
(iv) For chronic drug exposure, need values prior to
drug initiation
New-Onset AKI
Evidence of AKI without prior evidence of kidney
damage and calculated MDRD GFR $ 90 mL/min/
1.73 m2.
AKI-on-CKD
Evidence of AKI with criteria for kidney damage as
defined above, occurring in a patient with CKD criteria,
will be considered as AKI-on-CKD.
DEFINITION OF END OF TRIAL
The end of trial is the date of the last follow-up of the
last patient.
WITHDRAWAL OF PATIENTS/SUBJECTS
Patients may withdraw or may be withdrawn from the
study for any of the following reasons:
 Patient decides not to continue with the study
 Administrative decision by the investigator
 Significant protocol deviation
 Patient is unable to provide adequate blood sample
for DNA Case does not pass adjudication by adjudication
committeeASSESSMENT OF SAFETY
Because this is an observational cohort study, the main
risks include that of blood sampling and loss of confi-
dentiality. Measures will be taken to minimize those
risks. All adverse and serious adverse events will be
reported to the appropriate ethics committees.
GENETIC DATA MANAGEMENT AND QUALITY
CONTROL
Data management of the large amount of genotype data
and quality control (QC) will be performed using the
software PLINK.21 Initial data cleaning will include
multi-step standard procedures.22 In short, QC steps
include removal of samples and single nucleotide
polymorphisms (SNPs) with low genotyping quality,
genetic assessment of sex and ancestry to flag in-
consistencies with self-report, and assessment of
cryptic relatedness of subjects, and will result in a
filtered dataset of high quality.
PROCEDURE FOR ACCOUNTING OF MISSING
DATA
To maximize information present in our data and to
allow for a potential comparison of our results across
multiple studies genotyped on other platforms, we will
impute genotypes of SNPs not present on our array.
Imputation will be performed using IMPUTE2, a
method found to be especially useful in the context of
samples including mixed ancestries.23 Reference data
will include phased haplotypes from the 1000 Genomes
Project.24
Based on the distribution of our study sites, we
anticipate the inclusion of several major ethnic/racial
groups (Europeans/European Americans, African
Americans, Asians, and Hispanics) as well as admixed
individuals from different ancestries. It is well estab-
lished that allele frequencies across the genome can
vary among individuals of different ancestral groups,
and allelic association studies including subjects of
different biogeographic ancestry are at high risk for
this artifact. In addition, locus heterogeneity can lead
to false-negative results due to variation in genetic
backgrounds. We will take advantage of the large
amount of genotypic information available and will
control for potential population stratification in a 2-step
process.25 First, we will identify major groups of
subjects with similar biogeographic ancestry, using
approaches such as the program STRUCTURE.26 The
inclusion of population reference samples compiled
by our group27 will increase the power of these
approaches. Analyses are then conducted separately on
these more homogeneous ancestry groups, includingKidney International Reports (2016) 1, 288–298
L Awdishu et al.: DIRECT Study Design and Rationale CLINICAL RESEARCHprincipal components (PCs) derived from the program
EIGENSOFT v3.028 to control for additional population
stratification.
STATISTICAL ANALYSIS
In this observational cohort study, descriptive statistics
will be calculated for demographic and baseline char-
acteristics including the following: demographics;
baseline characteristics; past medical history; initial
health status measures; composition of sample and
patient location (e.g., surgical vs. medical ICU); con-
current care (e.g., medications, interventions including
surgery, and invasive procedures); drug exposure
(dose, frequency, route, timeline); renal function esti-
mates (Scr, GFR).
GENOMEWIDE ASSOCIATION STUDY
We will perform a GWAS to examine the association of
genetic variants with the risk for development of
DIKD. Mapping genetic determinants of DIKD requires
a multi-level approach, including an understanding of
interactions between environmental stressors (i.e., AKI
risk factors) and individual constitutional factors.
Logistic regression models will be used to test for as-
sociations between SNPs and case/control status under
the assumption of an additive genetic model. Initially, we
will adjust each phenotype for the typical covariates of
age, sex, indices of ancestry, and study cohort. Addi-
tional covariates predicted to be of high importance
include AKI risk factors such as volume status,
concomitant nephrotoxins, comorbidities such as dia-
betes or hypertension, and so forth. To assess significance
thresholds and to correct for multiple comparisons, we
will use conventional methods such as Bonferroni
correction for a genome-wide approach (i.e., P < 5
 108), permutation tests to derive an empirical level of
significance, and false-discovery rate analysis. PLINK
and R code will be used to conduct these analyses.
The highly polymorphic HLA system has been shown
to be especially important in adverse drug reactions. In
order to derive classical HLA alleles, we will take
advantage of the dense SNP coverage in the major his-
tocompatibility complex (MHC) region of the Illumina
Human Core plus Exome array. Specific methods as
developed by Zheng et al. take advantage of the extended
haplotype structure within the MHC to reliably predict
HLA alleles based on genotypes from these arrays.29
Sample Size
A total sample of approximately 800 patients will be
enrolled via 40 clinical centers worldwide. In previous
studies examining the genetic predisposition to drug-
induced liver injury (DILI) and serious skin reactions,
the associations between certain polymorphisms inKidney International Reports (2016) 1, 288–298HLA and aforementioned injuries were highly signifi-
cant.5,6 In a study of DILI caused by flucloxacillin,
possession of the HLA-B5701* allele was associated
with an odds ratio (OR) of 80.6 (95% confidence in-
terval [CI], 22.8284.9) for this adverse effect.5 The
HLA-A*3101 allele, with a prevalence of 2% to 5%
in Northern Europeans, was found to be a risk factor
for carbamazepine-induced hypersensitivity syndrome
(OR, 12.41; 95% CI, 1.27121.03), maculopapular ex-
anthema (OR, 8.33; 95% CI, 3.5919.36), and Stevens
Johnsontoxic epidermal necrosis (OR, 25.93; 95% CI,
4.93116.18).6
We conducted power calculations for our proposed
case-control association study based on a range of
realistic assumptions for trait heritability: assuming an
additive model, type I error rate of 5  108 for the
GWAS, perfect linkage disequilibrium between marker
and trait allele for common alleles (minor allele fre-
quency [MAF] 5%20%) and a disease prevalence of
20%. We conservatively base our calculations below
on n ¼ 6,000 POPRES controls, which are treated as
unselected population controls.30 However, we note
that at the time of analysis we will take advantage of
additional available control subjects, which will in-
crease the power of the study. Figure 2 shows the
number of subjects (cases plus controls) required to
achieve 80% power to detect a locus with a specific
genotype relative risk (GRR), considering a range of
number of cases and 6000 controls, respectively, for a
MAF of 20% (Figure 2a) and a MAF of 5% (Figure 2b),
which is typical for the HLA alleles. These calculations
are considering a joint analysis of all subjects together,
subsets of cases within a particular phenotype (N ¼
50600) as well as medication-specific analyses within
a drug class or specific drug (N ¼ 50600). Assuming
an incidence of 20% of an adverse reaction to a specific
medication, in a sample of N ¼ 600 cases and 6000
population controls, we would have 80% power to
detect a locus with a small GRR of 1.6 in the case of a
common SNP with MAF ¼ 20% (panel A). Power is
reduced for rare alleles, and we will have power to
detect a locus with a GRR of 1.98 in the case of a rare
allele with a MAF ¼ 5% (Figure 2b).DISCUSSION
The DIRECT study is the first cohort study designed to
evaluate whether there is a genetic basis for drug-
induced nephrotoxicity. Other networks have been
developed in DILI and serious skin injury, but large
networks for DIKD have not been previously estab-
lished. Many genetic studies on DIKD to date have
focused on single drugs or classes of drugs. The DIRECT
study is the first study to establish an international295
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Figure 2. Sample size estimation for the Genetic Contribution to Drug Induced Renal Injury (DIRECT) study. This figure demonstrates the
power estimates for individual drugs, drug classes, and phenotypes for common alleles. (a) minor allele frequency ¼ 20%, (b) minor allele
frequency ¼ 5%.
CLINICAL RESEARCH L Awdishu et al.: DIRECT Study Design and Rationalenetwork of centers enrolling cases of DIKD from a broad
range of drugs. Data from analysis of the genome will
provide preliminary information on significant genetic
polymorphisms associated with DIKD from each drug.
This will enhance our understanding of mechanisms of
toxicity for each drug. The DIRECT study will provide
preliminary information on target genes to further
validate the utility of genetic screening in addition to
current clinical testing for prediction of risk.
Strengths of the DIRECT study include the broad
enrollment of patients of different ages from various
clinical scenarios, standardization of the DIKD pheno-
type, detailed information on the course of injury and
clinical risk factors, and the causality assessment process.
With the inclusion of hospitalized and ambulatory care
patients with DIKD from various countries, the DIRECT
study will inform on the spectrum of DIKD, variation in
drug use and practice patterns in the different age groups
and countries. We anticipate variation in co-morbidities
and causal drugs in pediatric compared to adult
patients. In addition, drug use and practice patterns vary
internationally. We anticipate that genetic susceptibility
will vary by race and ethnicity. The DIRECT study will
capture a global snapshot from countries in North and
South Americas, Europe, and Asia.
The development of standardized phenotypes
for DIKD was critical to studying genetic susceptibil-
ity. All cases must meet standard criteria for enroll-
ment. Using inclusion criteria of stage 2 AKI will
improve the specificity of cases and enhance causality,
thereby increasing the likelihood of finding genetic296susceptibility. Moreover, phenotype standardization
will assist clinicians, researchers, industry, and regu-
latory bodies in designing future studies of DIKD.
The design of this study captures real-life clinical
scenarios including complex patients with multiple co-
morbidities, risk factors, and multi-drug injury. Acute
kidney injury is multi-factorial and requires assessment
of the contribution of competing risk factors to injury.
Detailed information on comorbidities, concurrent risk
factors, and the timing and extent of drug exposures
will enable the complete description of the spectrum of
injury in DIKD, risk factors for DIKD by causal drug,
and outcomes of injury.
The development of an adjudication process for
nephrotoxicity is novel and will provide insight into
causality assessment and attribution of risk. Clinical
adjudication has been previously used in AKI
biomarker studies, in which adjudicators are presented
with information on a patient’s Scr values and asked to
make a judgement as to whether AKI was present or
absent.31 However, adjudication of DIKD requires
additional consideration of all potential contributing
factors to AKI. Adjudication is a complex process
requiring evaluation of causality using published
criteria, including the following: strength of associa-
tion; temporality; consistency of the adverse event in
different subjects; specificity of the drug for the
adverse event; biological gradient for the effect (dos-
eresponse relationship); plausibility; coherence;
experimental evidence that can alter the adverse event;
and analogy between drugs of the same class.32 TheKidney International Reports (2016) 1, 288–298
L Awdishu et al.: DIRECT Study Design and Rationale CLINICAL RESEARCHgold standard for adjudication is expert consensus.
Two independent nephrologists will adjudicate each
case, with a third acting as a tiebreaker. Published
causality assessment tools will be used and compared to
one another for DIKD. These tools can help reduce
disagreement between adjudicators and classify the
relationship likelihood. A limitation of these general
causality assessment tools is lack of assessment of
competing risk factors. Acute kidney injury is a syn-
drome with multiple etiologies and many contributing
risk factors. Assessment of these risk factors improves
the specificity of cases and ultimately strengthens
causal association. However, the method for attributing
risk to each risk factor has not been previously delin-
eated, which may lead to variability in these assess-
ments. Adjudicator intra- and interrater reliability will
inform on the effectiveness of tools for causality
assessment. We developed case report forms for adju-
dication, which were pilot tested by 2 adjudicators and
refined for clarity (Supplementary Appendix S1). We
created a Web-based adjudication platform where ad-
judicators could access their randomly assigned cases.
All adjudicators were trained to complete the adjudi-
cation electronically in a blinded process. The data
from adjudication will capture the complexity of cau-
sality assessment in DIKD. The adjudication pass rates
for each of the causal drugs in DIKD will inform on the
complexity of cases and the consideration for sample
size determination in the design of future studies.
Limitations of this study include the lack of drug-
matched controls for GWAS as well as the lack of
validated causality assessment tools for nephrotoxicity.
We acknowledge that drug-matched controls would
enhance the ability to use drug exposure data in clin-
ical risk profiling. However, obtaining such controls
requires time and resources, and, given the low inci-
dence and the severity of nephrotoxicity, we opted to
use population-based controls, as this has been suc-
cessfully done in other studies of serious, rare adverse
events.5,6,10 In addition, the OR ranged from 8.33 to
80.6 for DILI and serious skin injury, which suggests
that the DIRECT study cohort size is adequate to detect
DIKD-associated polymorphisms with OR > 2. Vali-
dated causality assessment tools in DIKD are lacking.
The Naranjo et al.33 and Liverpool tools14 have not
been validated in DIKD but do perform well for
determining causality of general adverse drug events.
By using these tools in addition to the adjudication
process, we hope to refine the causality assessment of
DIKD leading to the development of validated tools.
Information obtained from causality assessment,
attribution of risk from concurrent risk factors, together
with genetic determinants of injury may be used to
develop predictive risk scores for DIKD. The results ofKidney International Reports (2016) 1, 288–298the DIRECT study may translate into safer patient out-
comes through individualization of therapy based on the
patient’s clinical risk factors and genotype.
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SUPPLEMENTARY MATERIAL
Supplementary Appendix S1. DIRECT study case report
forms.
Figure S1. Patient summary report. This figure captures
the patient summary report that is presented to
adjudicators at the time of adjudication. The data are
extracted from various case report forms and presented
in a visual format to summarize the patient’s medical
history, time course for drug exposure, trend in serum
creatinine (Scr), vital signs, concurrent acute kidney
injury (AKI) risk factors at each time point, and drug-
dosing history.
Supplementary material is linked to the online version of
the paper at http://www.kireports.org.
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